A Phase II, Single-arm, Japanese Multicenter Trial of TH-302 in Combination With Doxorubicin in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Phase of Trial: Phase II
Latest Information Update: 21 Dec 2018
Price : $35 *
At a glance
- Drugs Evofosfamide (Primary) ; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Sponsors Merck KGaA
- 16 Jun 2016 Status changed from recruiting to discontinued.
- 19 Oct 2015 Planned End Date changed from 1 Jan 2017 to 1 Jul 2017 as reported by ClinicalTrials.gov.
- 19 Oct 2015 Planned primary completion date changed from 1 Oct 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.